Comparative in vitro and in silico evaluation of the toxic effects of metformin and/or ascorbic acid, new treatment options in the treatment of Melasma

ArticleAçık Erişim

Özet

Melasma is a chronic condition that leads to the buildup of melanin pigment in the epidermis and dermis due to active melanocytes. Even though it is considered a non-life-threatening condition, pigment disorders have a negative impact on quality of life. Since melasma treatment is not sufficient and complicated, new treatment options are sought. Research on metformin and ascorbic acid suggested that they might be used against melasma in the scope of "drug repositioning."The MNT-1 human melanoma cell line was used to assess the effects of metformin, ascorbic acid, and metformin+ascorbic acid combination on cytotoxicity and oxidative stress. Melanin, cAMP, L-3,4-dihydroxyphenylalanine (L-DOPA) and tyrosinase levels were determined by commercial ELISA kits and tyrosinase gene expression was analyzed with RT-qPCR. Cytopathological evaluations were performed by phase contrast microscopy. Tyrosinase expression was determined by immunofluorescence (IF) staining of MNT-1 cells. The online service TargetNet was used for biological target screening. The parameters were not significantly altered by ascorbic acid applied at non-cytotoxic concentrations. On the contrary, metformin dramatically raised tyrosinase and intracellular ROS levels. Moreover, intracellular ROS levels and tyrosinase levels were found to be considerably elevated with the combined treatment. Also, potential metformin and ascorbic acid interactions were determined. According to the results, it can be said that these parameters were not significantly altered by ascorbic acid. On the contrary, metformin dramatically raised tyrosinase and intracellular oxidative stress levels. Moreover, intracellular oxidative stress and tyrosinase levels were elevated with the combined treatment. In conclusion, individual treatments of ascorbic acid or metformin may only provide a limited effect when treating melasma and extensive in vitro and in vivo research are required. © 2025 The Author(s).

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11270Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1093/toxres/tfaf025Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorYalçln, Hülya Tezel
dc.contributor.authorÇaklr, Deniz Arca
dc.contributor.authorYirün, Anll
dc.contributor.authorSanajou, Sonia
dc.contributor.authorIşlk, Gözde
dc.contributor.authorBozdemir, Özlem
dc.contributor.authorÖzçelik, Ibrahim
dc.contributor.authorGüdül Bacanll, Merve
dc.contributor.authorZeybek, Naciye Dilara
dc.contributor.authorBaydar, Terken
dc.contributor.authorErkekoǧlu, Plnar
dc.date.accessioned2026-10-18T20:26:20.557144704Z
dc.date.available2026-10-18T20:26:20.557144704Z
dc.date.issued2025
dc.description.abstractMelasma is a chronic condition that leads to the buildup of melanin pigment in the epidermis and dermis due to active melanocytes. Even though it is considered a non-life-threatening condition, pigment disorders have a negative impact on quality of life. Since melasma treatment is not sufficient and complicated, new treatment options are sought. Research on metformin and ascorbic acid suggested that they might be used against melasma in the scope of "drug repositioning."The MNT-1 human melanoma cell line was used to assess the effects of metformin, ascorbic acid, and metformin+ascorbic acid combination on cytotoxicity and oxidative stress. Melanin, cAMP, L-3,4-dihydroxyphenylalanine (L-DOPA) and tyrosinase levels were determined by commercial ELISA kits and tyrosinase gene expression was analyzed with RT-qPCR. Cytopathological evaluations were performed by phase contrast microscopy. Tyrosinase expression was determined by immunofluorescence (IF) staining of MNT-1 cells. The online service TargetNet was used for biological target screening. The parameters were not significantly altered by ascorbic acid applied at non-cytotoxic concentrations. On the contrary, metformin dramatically raised tyrosinase and intracellular ROS levels. Moreover, intracellular ROS levels and tyrosinase levels were found to be considerably elevated with the combined treatment. Also, potential metformin and ascorbic acid interactions were determined. According to the results, it can be said that these parameters were not significantly altered by ascorbic acid. On the contrary, metformin dramatically raised tyrosinase and intracellular oxidative stress levels. Moreover, intracellular oxidative stress and tyrosinase levels were elevated with the combined treatment. In conclusion, individual treatments of ascorbic acid or metformin may only provide a limited effect when treating melasma and extensive in vitro and in vivo research are required. © 2025 The Author(s).
dc.identifier.doi10.1093/toxres/tfaf025
dc.identifier.eissn2045-4538
dc.identifier.issn2045-452X
dc.identifier.issue1
dc.identifier.pmcidPMC11878769
dc.identifier.pmid40040652
dc.identifier.scopus2-s2.0-86000152198
dc.identifier.startpagetfaf025
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11270
dc.identifier.volume14
dc.identifier.wosWOS:001436396600001
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofToxicology Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectascorbic acid
dc.subjecthyperpigmentation
dc.subjectIn silico
dc.subjectIn vitro
dc.subjectmetformin
dc.subjectMNT-1 cells
dc.subjectcyclic AMP
dc.subjectlevodopa
dc.subjectmelanin
dc.subjectmessenger RNA
dc.subjectmonophenol monooxygenase
dc.subjectreactive oxygen metabolite
dc.subjectArticle
dc.subjectcaiman
dc.subjectchloasma
dc.subjectcomputer model
dc.subjectcontrolled study
dc.subjectcytopathology
dc.subjectcytotoxic concentration
dc.subjectdermis
dc.subjectdrug cytotoxicity
dc.subjectdrug repositioning
dc.subjectepidermis
dc.subjectfluorescence intensity
dc.subjectgene expression
dc.subjecthuman
dc.subjecthuman cell
dc.subjectimmunofluorescence
dc.subjectimmunofluorescence microscopy
dc.subjectimmunohistochemistry
dc.titleComparative in vitro and in silico evaluation of the toxic effects of metformin and/or ascorbic acid, new treatment options in the treatment of Melasma
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus3
rdl.citation.wos2
rdl.departmentFaculty of Pharmacy, Department of Toxicology, Erzincan Binali Yildirim University, Yalnızbağ Erzincan 24002, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)